 | Roy D AltmanShow email addressRonal Reagan UCLA Med. Ctr., Los Angeles, CA | Ronald Reagan UCLA Med. Ctr., Los Angeles, CA | Div. of Rheumatology and Immunology, Univ. of California, Los Angeles, 90095, CA ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Roy D Altman:Expert Impact
Concepts for whichRoy D Altmanhas direct influence:Knee osteoarthritis,Hyaluronic acid,Knee pain,Supartz fx,Osteoarthritis knee,Task force,Responder criteria,United states.
Roy D Altman:KOL impact
Concepts related to the work of other authors for whichfor which Roy D Altman has influence:Knee osteoarthritis,Rheumatoid arthritis,Hyaluronic acid,Articular cartilage,Synovial fluid,Chronic pain,Physical activity.
KOL Resume for Roy D Altman
| Year | |
|---|---|
| 2022 | Ronal Reagan UCLA Med. Ctr., Los Angeles, CA |
| 2021 | Ronald Reagan UCLA Medical Center, Los Angeles, CA USA |
| 2020 | Department of Medicine, Division of Rheumatology, University of California, Los Angeles, CA, USA Ronald Reagan UCLA Medical Center, Los Angeles, California |
| 2019 | Division of Rheumatology and Immunology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA. From the *David Geffen School of Medicine, University of California, Los Angeles; and †Scripps Clinic Medical Group, La Jolla, CA. |
| 2018 | Academic Speakers of America, Agua Dulce, CA, USA Division of Rheumatology and Immunology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA. Electronic address: |
| 2017 | David Geffen School of Medicine, University of California, Los Angeles |
| 2016 | Division of Rheumatology and Immunology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA Ronald Reagan UCLA Medical Center, Los Angeles, California. |
| 2015 | David Geffen School of Medicine, University of California, Los Angeles, CA Department of Medicine, University of California at Los Angeles, Los Angeles, California. |
| 2014 | Department of Medicine/Rheumatology, UCLA, Rehabilitation Building, 1000 Veteran Avenue, 91390, Los Angeles, CA, USA UCLA Medical Center RHU, Los Angeles, CA David Geffen School of Medicine, University of California Los Angeles |
| 2013 | UCLA Medical Center RHU, 200 UCLA Medical Plaza, 365-B, 90095, Los Angeles, CA, USA |
| 2012 | From the *Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, OH; †Department of Rheumatology, University of California at Los Angeles, CA; and ‡Department of Quantitative Health Sciences/Biostatistics, Cleveland Clinic, OH. |
| 2011 | Division of Rheumatology and Immunology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, United States David Geffen School of Medicine, University of California, Los Angeles, California, USA Medical Director, Arthritis Research UK, Chesterfield, UK; Professor, Rheumatic Diseases Epidemiology, University of Manchester, Manchester, UK Chairman, Second Department of Medicine, Center for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria |
| 2010 | David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Affiliations for Committee members' can be found in the following section: Members of the OARSI Treatment Guidelines Committee University of California, Los Angeles, 1000 Veterans Avenue, Los Angeles, CA 90024, USA |
| 2009 | Department of Rheumatology and Immunology, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA. Division of Rheumatology and Immunology, University of California, Los Angeles, Los Angeles, California |
| 2008 | David Geffen School of Medicine, University of California, Los Angeles, CA, United States West Bald Mountain Court, Agua Dulce, CA 91390 Professor of Medicine, Division of Rheumatology and Immunology, University of California, Los Angeles (UCLA), USA University of Edinburgh, Osteoarticular Research Group, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom |
| 2007 | The David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, CA, USA |
| 2006 | Professor of Medicine, Division of Immunology and Rheumatology, University of California, Los Angeles, CA. Osteoarthritis and Cartilage, 9854 West Bald Mountain Ct., Agua Dulce, CA 91390, USA |
| 2005 | University of California at Los Angeles |
| 2004 | Miami VAMC and University of Miami, Miami, Florida Division of Rheumatology, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA, USA |
| 2003 | University of Miami, Miami, FL, USA |
| 2002 | Geriatric Research. Education and Clinical Center, Miami Veterans Medical Center, 1201 NW 16 St. (NH207G), 22125, Miami, FL University of Miami School of Medicine, Miami, Florida |
| 2001 | University of Miami, Miami Veterans Administration Medical Center, Miami, FL |
| Concept | World rank |
|---|---|
| glucosamines efficacy | #1 |
| euflexxa patients 2 | #1 |
| collagens abr animals | #1 |
| madaus product | #1 |
| abr animals types | #1 |
| lowdose gpc | #1 |
| knee practice | #1 |
| abr reduced amounts | #1 |
| brand trials | #1 |
| rs3pe polymyalgia rheumatica | #1 |
| moderate pain paracetamol | #1 |
| bioha 38741 qaly | #1 |
| bone common reason | #1 |
| work composition recommendations | #1 |
| medicare knee | #1 |
| repeated administration risedronate | #1 |
| structure modifying gpc | #1 |
| analgesics narcotic double | #1 |
| initial alkaline phosphatase | #1 |
| diagnosis tkr | #1 |
| hyaluronic acid efficacy | #1 |
| rs3pe small doses | #1 |
| clinical benefit saline | #1 |
| actions hgf | #1 |
| pain pagets disease | #1 |
| united states capsaicin | #1 |
| diarrhoea diacerein | #1 |
| oah progression | #1 |
| product formulation salt | #1 |
| pathophysiologic patients symptoms | #1 |
| hand function osteoarthritis | #1 |
| bioengineered hyaluronic acid | #1 |
| oah australian | #1 |
| injection hyaluronate | #1 |
| tkr surgery cohort | #1 |
| meniscectomy years | #1 |
| capsaicintreated patients week | #1 |
| 7 months time | #1 |
| patients ginger extract | #1 |
| cartilage oedema | #1 |
| threemonth efficacy | #1 |
| disease cartilagenous bony | #1 |
| symptomatic treatment pain | #1 |
| aging worlds population | #1 |
| abr abr animals | #1 |
| articular damage article | #1 |
| patient function evidence | #1 |
| physician pagets disease | #1 |
| ka longer time | #1 |
| additional primary endpoint | #1 |
| Sign-in to see all concepts, it's free! | |
Prominent publications by Roy D Altman
PURPOSE: As a prelude to developing updated, evidence-based, international consensus recommendations for the management of hip and knee osteoarthritis (OA), the Osteoarthritis Research Society International (OARSI) Treatment Guidelines Committee undertook a critical appraisal of published guidelines and a systematic review (SR) of more recent evidence for relevant therapies.
METHODS: Sixteen experts from four medical disciplines (primary care two, rheumatology 11, orthopaedics one and ...
| Known for Critical Appraisal | Knee Osteoarthritis | Treatment Guidelines | Oarsi Recommendations | Management Hip |
OBJECTIVE: To update the American College of Rheumatology (ACR) 2000 recommendations for hip and knee osteoarthritis (OA) and develop new recommendations for hand OA.
METHODS: A list of pharmacologic and nonpharmacologic modalities commonly used to manage knee, hip, and hand OA as well as clinical scenarios representing patients with symptomatic hand, hip, and knee OA were generated. Systematic evidence-based literature reviews were conducted by a working group at the Institute of ...
| Known for Knee Hip | Management Patients | Recommendations Evidence | Pharmacologic Modalities | Osteoarthritis Hand |
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines
[ PUBLICATION ]
PURPOSE: To develop concise, patient-focussed, up to date, evidence-based, expert consensus recommendations for the management of hip and knee osteoarthritis (OA), which are adaptable and designed to assist physicians and allied health care professionals in general and specialist practise throughout the world.
METHODS: Sixteen experts from four medical disciplines (primary care, rheumatology, orthopaedics and evidence-based medicine), two continents and six countries (USA, UK, France, ...
| Known for Consensus Guidelines | Knee Osteoarthritis | Management Hip | Based Evidence | Chondroitin Sulphate |
Safety and Efficacy of Topical Diclofenac Sodium Gel for Knee Osteoarthritis in Elderly and Younger Patients
[ PUBLICATION ]
Background: NSAIDs used for the treatment of osteoarthritis (OA) have dose-related risks for gastrointestinal, cardiovascular and renal adverse events (AEs), particularly in elderly patients. Topical NSAIDs reduce systemic NSAID exposure and may mitigate these risks.Objective: To evaluate the safety and efficacy of topical diclofenac sodium 1% gel (DSG) versus vehicle in patients aged 25–64 or ≥65 years who have been diagnosed with knee OA.Study Design: Pooled data from three 12-week, ...
| Known for Knee Osteoarthritis | Dsg Patients | Topical Diclofenac | Womac Pain | Inflammatory Agents |
Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis
[ PUBLICATION ]
INTRODUCTION: Nonsteroidal anti-inflammatory drugs are recommended for the relief of pain associated with hand osteoarthritis (OA) but do not alter the underlying structural changes that contribute to impaired physical function. The current analysis examined the relationship of pain relief with measures of function and global rating of disease in patients with hand OA.
METHODS: This was a combined analysis of 2 prospective, randomized, double-blind, 8-week, multicenter, parallel-group ...
| Known for Physical Function | Pain Relief | Hand Osteoarthritis | Antiinflammatory Agents | Outcome Measures |
The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip
[ PUBLICATION ]
Clinical criteria for the classification of patients with hip pain associated with osteoarthritis (OA) were developed through a multicenter study. Data from 201 patients who had experienced hip pain for most days of the prior month were analyzed. The comparison group of patients had other causes of hip pain, such as rheumatoid arthritis or spondylarthropathy. Variables from the medical history, physical examination, laboratory tests, and radiographs were used to develop different sets of ...
| Known for Clinical Criteria | Sensitivity Specificity | Hip Hip Pain | Classification Tree | Osteophytes Patients |
BACKGROUND: The relation between knee meniscal structural damage and cartilage degradation is plausible but not yet clearly proven.
OBJECTIVES: To quantitate the cartilage volume changes in knee osteoarthritis using magnetic resonance imaging (MRI), and determine whether meniscal alteration predicts cartilage volume loss over time.
METHODS: 32 patients meeting ACR criteria for symptomatic knee osteoarthritis were studied. MRI knee acquisitions were done every six months for two years. ...
| Known for Meniscal Tear | Symptomatic Knee Osteoarthritis | Magnetic Resonance | Cartilage Volume | 24 Patients |
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee
[ PUBLICATION ]
OBJECTIVE: To develop an evidence-based guideline for the comprehensive management of osteoarthritis (OA) as a collaboration between the American College of Rheumatology (ACR) and the Arthritis Foundation, updating the 2012 ACR recommendations for the management of hand, hip, and knee OA.
METHODS: We identified clinically relevant population, intervention, comparator, outcomes questions and critical outcomes in OA. A Literature Review Team performed a systematic literature review to ...
| Known for Patients Knee | Osteoarthritis Hand | Cmc Joint | Literature Review | Recommendations Management |
OBJECTIVE: Non-animal stabilized hyaluronic acid (NASHA) is a novel hyaluronan (HA) preparation with a 4-week intra-articular half-life. This study compared the efficacy of a single injection of NASHA with placebo in patients with osteoarthritis (OA) of the knee.
DESIGN: This was a 26-week randomized, double-blind, multicenter study of a single intra-articular knee injection with either NASHA or placebo (saline). Assessments included the Western Ontario McMasters Universities ...
| Known for Nasha Placebo | Articular Injection | Patients Knee | Single Intra | Hyaluronic Acid |
A randomized saline-controlled trial of NASHA hyaluronic acid for knee osteoarthritis
[ PUBLICATION ]
OBJECTIVE: NASHA hyaluronic acid is administered as a single intra-articular injection to treat the symptoms of osteoarthritis (OA). In a previous trial, post-hoc analysis indicated that NASHA provides significantly greater pain relief than saline in patients with OA confined to the study knee. We aimed to evaluate the safety and efficacy of NASHA in patients with unilateral knee OA.
RESEARCH DESIGN AND METHODS: This was a randomized, double-blind, saline-controlled trial. All patients ...
| Known for Nasha Hyaluronic Acid | Knee Pain | Intra Articular | Saline Patients | Aged Osteoarthritis |
OBJECTIVE: To report the FLEXX trial, the first well-controlled study assessing the safety and efficacy of Euflexxa (1% sodium hyaluronate; IA-BioHA) therapy for knee osteoarthritis (OA) at 26 weeks.
METHODS: This was a randomized, double-blind, multicenter, saline-controlled study. Subjects with chronic knee OA were randomized to 3 weekly intra-articular (IA) injections of either buffered saline (IA-SA) or IA-BioHA (20 mg/2 ml). The primary efficacy outcome was subject recorded ...
| Known for Flexx Trial | Painful Osteoarthritis | Iasa Iabioha | Efficacy Safety | 26 Weeks |
BACKGROUND: The growing prevalence of osteoarthritis (OA) and the medical costs associated with total knee replacement (TKR) surgery for end-stage OA motivate a search for agents that can delay OA progression. We test a hypothesis that hyaluronic acid (HA) injection is associated with delay of TKR in a dose-dependent manner.
METHODS AND FINDINGS: We retrospectively evaluated records in an administrative claims database of ~79 million patients, to identify all patients with knee OA who ...
| Known for Patients Knee | Hyaluronic Acid | Time Tkr | Claims Database | Aged Osteoarthritis |
Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial.
[ PUBLICATION ]
OBJECTIVE: To measure the efficacy and safety of diclofenac sodium gel in patients with primary hand osteoarthritis (OA).
METHODS: In a randomized, double-blind, placebo-controlled trial, men and women aged > or = 40 years diagnosed with primary OA in the dominant hand were randomly assigned to self-apply topical 1% diclofenac sodium gel (Voltaren Gel) (n = 198) or vehicle (n = 187) to both hands 4 times daily for 8 weeks. Primary outcome measures included OA pain intensity (100-mm ...
| Known for Diclofenac Sodium Gel | Hand Osteoarthritis | Pain Intensity | Antiinflammatory Agents | Global Rating |
